Edmunds W J, Pebody R G, Aggerback H, Baron S, Berbers G, Conyn-van Spaendonck M A, Hallander H O, Olander R, Maple P A, Melker H E, Olin P, Fievret-Groyne F, Rota C, Salmaso S, Tischer A, von-Hunolstein C, Miller E
PHLS Communicable Disease Surveillance Centre, London, UK.
Epidemiol Infect. 2000 Aug;125(1):113-25. doi: 10.1017/s0950268899004161.
Seven countries in Western Europe collected large, representative serum banks across the entire age range and tested them for diphtheria anti-toxin (sample size ranged from 2991 to 7715). Although a variety of assays were used, the results were all standardized to those of a reference laboratory and expressed in international units. The standardization process, and the availability of similar, large data sets allowed comparative analyses to be performed in which a high degree of confidence could be ascribed to observed epidemiological differences. The results showed that there were large differences in the proportion of adults with insufficient levels of protection amongst different countries. For instance, roughly 35% of 50- to 60-year-olds were found to be seronegative (titre < or = 0.01 IU/ml) in Finland compared with 70-75% in the United Kingdom. Furthermore, the proportion of seronegative adults would be expected to increase in some countries, notably Italy and the western part of Germany. In those countries with vaccination of military recruits there was a marked sex-related difference in the proportion of seropositive individuals. All countries have high levels of infant vaccine coverage (> 90%) but the accelerated schedule in the United Kingdom appears to result in lower anti-toxin titres than elsewhere. In Sweden, booster doses are not offered until 10 years of age which results in large numbers of children with inadequate levels of protection. Although the United Kingdom and Sweden both have higher proportions of seronegative children than elsewhere the likelihood of a resurgence of diphtheria in these countries seems remote.
西欧的七个国家收集了涵盖所有年龄段的具有代表性的大型血清库,并对其进行白喉抗毒素检测(样本量从2991至7715不等)。尽管使用了多种检测方法,但结果都按照一个参考实验室的标准进行了标准化,并以国际单位表示。标准化过程以及类似大型数据集的可得性使得能够进行比较分析,从而可以高度确信所观察到的流行病学差异。结果显示,不同国家中保护水平不足的成年人比例存在很大差异。例如,在芬兰,50至60岁人群中约35%的人血清学检测呈阴性(效价≤0.01 IU/ml),而在英国这一比例为70 - 75%。此外,预计在一些国家,特别是意大利和德国西部,血清学检测呈阴性的成年人比例将会增加。在那些对新兵进行疫苗接种的国家,血清学检测呈阳性的个体比例存在明显的性别差异。所有国家的婴儿疫苗接种覆盖率都很高(>90%),但英国的加速接种程序似乎导致抗毒素效价比其他地方更低。在瑞典,直到10岁才提供加强剂量疫苗,这导致大量儿童的保护水平不足。尽管英国和瑞典血清学检测呈阴性的儿童比例都高于其他地方,但在这些国家白喉卷土重来的可能性似乎很小。